Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma

Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma

(2020) Christine I Chen et al.   BLOOD

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

(2019) Ujjawal H. Gandhi et al.   LEUKEMIA

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

(2019) Andrzej J. Jakubowiak et al.   BRITISH JOURNAL OF HAEMATOLOGY

Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies

(2019) Alessandro Allegra et al.   Clinical Lymphoma Myeloma & Leukemia

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

(2019) Ajai Chari et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)

(2019) Cristina Gasparetto et al.   BLOOD

Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma

(2019) Darrell J White et al.   BLOOD

Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

(2019) Ajai Chari et al.   BLOOD

Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma

(2018) Ujjawal H. Gandhi et al.   Clinical Lymphoma Myeloma & Leukemia

Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis

(2018) Marjorie Pick et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

(2018) Dan T. Vogl et al.   JOURNAL OF CLINICAL ONCOLOGY

Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death

(2018) Christian Argueta et al.   Oncotarget

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

(2018) Nizar J. Bahlis et al.   BLOOD

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

(2017) S K Kumar et al.   LEUKEMIA

CSN1 Somatic Mutations in Penile Squamous Cell Carcinoma

(2016) A. Feber et al.   CANCER RESEARCH

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

(2016) Joel G. Turner et al.   Journal of Hematology & Oncology

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells

(2016) J Etchin et al.   LEUKEMIA

Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies

(2016) Z A Hing et al.   LEUKEMIA

Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma

(2016) S. Li et al.   MOLECULAR CANCER THERAPEUTICS

XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer

(2016) Jimi Kim et al.   NATURE

Importins and exportins as therapeutic targets in cancer

(2016) Amit Mahipal et al.   PHARMACOLOGY & THERAPEUTICS

Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export

(2016) Jasper Edgar Neggers et al.   Oncotarget

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death

(2016) Trinayan Kashyap et al.   Oncotarget

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma

(2016) Joel G. Turner et al.   Oncotarget

Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing

(2015) Jasper E. Neggers et al.   CHEMISTRY & BIOLOGY

Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling

(2015) F. Conforti et al.   CLINICAL CANCER RESEARCH

Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor

(2015) S. Rosebeck et al.   MOLECULAR CANCER THERAPEUTICS

Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms

(2015) Jahangir Abdi et al.   Oncotarget

Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma

(2014) Mariko Yoshimura et al.   CANCER SCIENCE

Meta-Analysis of the Efficacy and Safety of Bortezomib Re-Treatment in Patients With Multiple Myeloma

(2014) Kevin B. Knopf et al.   Clinical Lymphoma Myeloma & Leukemia

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Nucleo-cytoplasmic transport as a therapeutic target of cancer

(2014) Giovanni Luca Gravina et al.   Journal of Hematology & Oncology

Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents

(2014) Joel G. Turner et al.   SEMINARS IN CANCER BIOLOGY

Clinical translation of nuclear export inhibitors in cancer

(2014) William T. Senapedis et al.   SEMINARS IN CANCER BIOLOGY

Promising SINEs for Embargoing Nuclear-Cytoplasmic Export as an Anticancer Strategy

(2014) D. S. P. Tan et al.   Cancer Discovery

Prognostic impact and targeting of CRM1 in acute myeloid leukemia

(2013) K. Kojima et al.   BLOOD

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

(2013) J Schmidt et al.   LEUKEMIA

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

(2013) Y-T Tai et al.   LEUKEMIA

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

(2012) M. Chesi et al.   BLOOD

Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors

(2012) Ori Kalid et al.   JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

Sequence and structural analyses of nuclear export signals in the NESdb database

(2012) Darui Xu et al.   MOLECULAR BIOLOGY OF THE CELL

Importin 7 and Exportin 1 Link c-Myc and p53 to Regulation of Ribosomal Biogenesis

(2012) Lior Golomb et al.   MOLECULAR CELL

The Oncogene eIF4E Reprograms the Nuclear Pore Complex to Promote mRNA Export and Oncogenic Transformation

(2012) Biljana Culjkovic-Kraljacic et al.   Cell Reports

Nuclear export of proteins and drug resistance in cancer

(2011) Joel G. Turner et al.   BIOCHEMICAL PHARMACOLOGY

Identification of Molecular Vulnerabilities in Human Multiple Myeloma Cells by RNA Interference Lethality Screening of the Druggable Genome

(2011) R. E. Tiedemann et al.   CANCER RESEARCH

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Structural basis for leucine-rich nuclear export signal recognition by CRM1

(2009) Xiuhua Dong et al.   NATURE

Structural basis for assembly and disassembly of the CRM1 nuclear export complex

(2009) Xiuhua Dong et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer

(2008) Aurelia Noske et al.   CANCER

Bortezomib-Resistant Nuclear Factor- B Activity in Multiple Myeloma Cells

(2008) S. Markovina et al.   MOLECULAR CANCER RESEARCH